News und Analysen
Correction of a release from 02.01.2020, 09:55 CET/CEST - Sartorius Stedim Biotech SA: ANNUAL REPORT OF THE LIQUIDITY CONTRACT WITH THE STOCKBROKER COMPANY GILBERT DUPONT
Correction of a release from 02.01.2020, 09:55 CET/CEST - Sartorius Stedim Biotech SA: ANNUAL REPORT OF THE LIQUIDITY CONTRACT WITH THE STOCKBROKER COMPANY GILBERT DUPONT
Sartorius Stedim Biotech SA: ANNUAL REPORT OF THE LIQUIDITY CONTRACT WITH THE STOCKBROKER COMPANY GILBERT DUPONT
Sartorius Stedim Biotech SA: ANNUAL REPORT OF THE LIQUIDITY CONTRACT WITH THE STOCKBROKER COMPANY GILBERT DUPONT
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
DGAP-News: Biom'up announces the approval of HEMOBLAST(TM) Bellows and its laparoscopic applicator in Australia
DGAP-News: Biom'up announces the approval of HEMOBLAST(TM) Bellows and its laparoscopic applicator in Australia
Sartorius Stedim Biotech Capital Markets: Links to presentation and webcast
Sartorius Stedim Biotech Capital Markets: Links to presentation and webcast
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech publishes unaudited first quarter results for 2024
Sartorius Stedim Biotech publishes unaudited first quarter results for 2024
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Resolutions of the Annual Shareholders’ Meeting of Sartorius Stedim Biotech S.A.
Resolutions of the Annual Shareholders’ Meeting of Sartorius Stedim Biotech S.A.
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
Sartorius Stedim Biotech SA: Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
Sartorius Stedim Biotech releases Universal Registration Document 2023
Sartorius Stedim Biotech releases Universal Registration Document 2023
Sartorius Stedim Biotech: Information on Document Availability
Sartorius Stedim Biotech: Information on Document Availability
Board of Directors of Sartorius Stedim Biotech resolves to propose a dividend of 0.69 euros per share to the Annual Shareholders’ Meeting
Board of Directors of Sartorius Stedim Biotech resolves to propose a dividend of 0.69 euros per share to the Annual Shareholders’ Meeting
Sartorius Stedim Biotech SA: Sartorius Stedim Biotech S.A. successfully completes a EUR 1.2 billion share capital increase without shareholders’ preferential subscription rights
Sartorius Stedim Biotech SA: Sartorius Stedim Biotech S.A. successfully completes a EUR 1.2 billion share capital increase without shareholders’ preferential subscription rights
Sartorius Stedim Biotech S.A. announces an offering of approximately 1.2 billion euros of new shares without shareholders’ preferential subscription rights by means of an accelerated bookbuilding
Sartorius Stedim Biotech S.A. announces an offering of approximately 1.2 billion euros of new shares without shareholders’ preferential subscription rights by means of an accelerated bookbuilding
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech publishes preliminary, unaudited results for fiscal 2023 and provides 2024 guidance as well as new midterm outlook
Sartorius Stedim Biotech publishes preliminary, unaudited results for fiscal 2023 and provides 2024 guidance as well as new midterm outlook
Sartorius Stedim Biotech SA: Half-year liquidity contract statement for Sartorius Stedim Biotech
Sartorius Stedim Biotech SA: Half-year liquidity contract statement for Sartorius Stedim Biotech
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: Nine-month results 2023 of Sartorius Stedim Biotech
Sartorius Stedim Biotech SA: Nine-month results 2023 of Sartorius Stedim Biotech